Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy

(2018) Nadia Madrid-Elena et al.   JOURNAL OF VIROLOGY

Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs

(2017) G. Tapia et al.   JOURNAL OF INFECTION

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

(2017) María Rosa López-Huertas et al.   Scientific Reports

Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4+ T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb

(2016) Md Saha Jamaluddin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Disulfiram';s Anticancer Activity: Evidence and Mechanisms

(2016) Yang Jiao et al.   Anti-Cancer Agents in Medicinal Chemistry

HIV-1 latent reservoir: size matters

(2016) Flavia Hodel et al.   Future Virology

Defective proviruses rapidly accumulate during acute HIV-1 infection

(2016) Katherine M Bruner et al.   NATURE MEDICINE

Clonally expanded CD4+T cells can produce infectious HIV-1 in vivo

(2016) Francesco R. Simonetti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broad activation of latent HIV-1 in vivo

(2016) Kirston Barton et al.   Nature Communications

IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle

(2016) Mayte Coiras et al.   Cell Reports

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes

(2016) R. Brad Jones et al.   PLoS Pathogens

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function

(2016) Carolina Garrido et al.   Frontiers in Immunology

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial

(2016) Steffen Leth et al.   Lancet HIV

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

(2016) Héloïse M. Delagrèverie et al.   Open Forum Infectious Diseases

The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA Is Not Influenced by Age

(2015) José-Ramón Blanco et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients

(2015) Adam M. Spivak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 functional cure: will the dream come true?

(2015) Chao Liu et al.   BMC Medicine

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir

(2015) Julia A. Sung et al.   JOURNAL OF INFECTIOUS DISEASES

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

(2015) Gilles Darcis et al.   PLoS Pathogens

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

(2015) Julian H Elliott et al.   Lancet HIV

Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

(2014) Timothy J. Henrich et al.   ANNALS OF INTERNAL MEDICINE

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 persistence in CD4+ T cells with stem cell–like properties

(2014) Maria J Buzon et al.   NATURE MEDICINE

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes

(2014) Richard Brad Jones et al.   PLoS Pathogens

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial

(2014) Alain Lafeuillade et al.   AIDS Research and Therapy

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Interleukin-7 promotes HIV persistence during antiretroviral therapy

(2013) C. Vandergeeten et al.   BLOOD

Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure

(2013) Ya-Chi Ho et al.   CELL

A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy

(2013) A. M. Spivak et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 transcription and latency: an update

(2013) Carine Van Lint et al.   Retrovirology

Combined approaches for HIV cure

(2013) David M. Margolis et al.   Current Opinion in HIV and AIDS

24 Hours in the Life of HIV-1 in a T Cell Line

(2013) Pejman Mohammadi et al.   PLoS Pathogens

An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

(2013) Celsa A. Spina et al.   PLoS Pathogens

Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay

(2013) Gregory M. Laird et al.   PLoS Pathogens

Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog

(2012) Geneviève Doyon et al.   AIDS

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients

(2012) Steven FL van Lelyveld et al.   Expert Review of Anti-Infective Therapy

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load

(2012) Paola Vitiello et al.   INTERVIROLOGY

Shock and kill

(2012) Steven G. Deeks   NATURE

Protein Kinase Cθ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+T Lymphocytes

(2011) María Rosa López-Huertas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation

(2011) S. Xing et al.   JOURNAL OF VIROLOGY

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

(2011) Carolina Gutiérrez et al.   PLoS One

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells

(2011) Suha Saleh et al.   Retrovirology

Long-Term Immunovirogical Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice

(2010) Miguel Genebat et al.   CURRENT HIV RESEARCH

New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection

(2010) Javier Garcia-Perez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells

(2010) Alberto Bosque et al.   METHODS

Ex vivo T cell–based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses

(2010) Asier Sáez-Cirión et al.   Nature Protocols

Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton

(2010) P. U. Cameron et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth

(2010) Jianqing Lin et al.   PROSTATE

Establishment and maintenance of HIV latency: model systems and opportunities for intervention

(2009) Matthew D Marsden et al.   Future Virology

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

(2009) Mayte Coiras et al.   NATURE REVIEWS MICROBIOLOGY

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA